+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 31Oct
    Newron Pharmaceuticals hosts its 2018 R&D Day in New York City

  • 30Oct
    Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m

     

  • 23Oct
    Meiji Seika and Eisai announce submission of manufacturing and marketing approval application in Japan for safinamide in Parkinson’s disease

  • 15Oct
    Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York

     

  • 8Oct
    Newron Dedicates Efforts to Research and Advocacy During Rett Awareness Month in October

     

  • 25Sep
    Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

View All

Newron share price

Events

  • 3Dec
    Global Mizuho Investor Conference (MIC) 2018

    December 3 & 4, Lotte New York Palace, New York, NY, USA

  • 14Nov
    Jefferies 2018 London Healthcare Conference

    November 14-15, 2018 - the Waldorf Hilton, London, UK

  • 31Oct
    2018 R&D Day hosted by Newron

    October 31, 2018 - New York, USA

View Event Calendar